Clinical Scorecard: Utilization of Ovine Forestomach Matrix Implant for Surgical Treatment of Perianal Fistulas
At a Glance
Category
Detail
Condition
Cryptoglandular perianal fistulas (PF)
Key Mechanisms
Use of ovine forestomach matrix (OFM), a decellularized extracellular matrix biomaterial, as a minimally invasive implant to facilitate fistula closure by promoting tissue regeneration and remodeling
Target Population
Patients with cryptoglandular perianal fistulas, including those with complicating comorbidities
Care Setting
Surgical outpatient or hospital setting with anesthesia and follow-up care
Key Highlights
Traditional surgical treatments for PF have high recurrence and risk of sphincter injury; less invasive methods often have lower efficacy.
OFM is a bio-absorbable, regenerative biomaterial previously used in contaminated and inflamed soft tissue wounds.
This case series is the first reported use of OFM as a perianal fistula implant (PAFI) aiming to minimize complications and avoid invasive surgery.
Guideline-Based Recommendations
Diagnosis
Evaluate fistula tract via physical examination under anesthesia and/or seton placement; MRI not routinely required.
Exclude patients with gross infection or persistent purulent discharge before OFM implant use.
Management
Prepare fistula with a non-cutting seton left in place for at least 12 weeks prior to implant.
Debride fistula tract to remove epithelial lining before OFM implant insertion.
Hydrate and roll OFM graft to match fistula tract dimensions; secure implant via sutures attached to seton.
Administer local anesthesia including bilateral pudendal and circumferential perianal block.
No postoperative dressing; patients wear surgical underwear.
Monitoring & Follow-up
Follow-up visits at 2 weeks, 8 weeks, 6 months, and 12 months postoperatively to assess healing and complications.
Risks
Avoid use in presence of active infection to prevent complications.
Potential postoperative complications include infection, bleeding, pain, and fistula recurrence.
Patient & Prescribing Data
Fourteen patients (10 male, 4 female), mean age 56.5 years, with isolated trans-sphincteric PF mostly; some with comorbidities such as diabetes, obesity, psychiatric disorders.
OFM implant used as a minimally invasive alternative to traditional surgery with the goal of complete healing by 8 weeks and reduced postoperative complications.
Clinical Best Practices
Ensure fistula tract is free of gross infection before OFM implant placement.
Use non-cutting seton for at least 12 weeks to prepare fistula tract.
Perform careful debridement of fistula tract epithelium to optimize implant integration.
Tailor OFM implant size to fistula tract dimensions for effective occlusion.
Secure implant internally and externally with sutures to maintain position.
Provide adequate local anesthesia and postoperative pain control.
Conduct scheduled follow-up visits to monitor healing and detect recurrence early.
